Companies /Healthcare

CRISPR Therapeutics AG

NASDAQ: CRSP Biotechnology
$59.53
â–² $0.30 (+0.51%) today
Markets open · 2:27pm ET

Q2 2026 Earnings

Reported Aug 3, 2026, 4:24pm ET · SEC source
$-0.94
Beat +20.59%
EPS · est. $-1.18
$10.2M
Beat +37.03%
Revenue · est. $7.4M
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%Aug 3Aug 4report 4:24pm ETearnings+1.8%+4.2%
−3%0+3%Aug 3Aug 4earnings+1.8%+4.2%
CRSP +4.2%S&P 500 +1.8%
−3%0+3%Aug 3Aug 4report 4:24pm ETearnings+3.0%+4.2%
−3%0+3%Aug 3Aug 4earnings+3.0%+4.2%
CRSP +4.2%NASDAQ +3.0%
−4%0+4%+8%Aug 3Aug 11report 4:24pm ETearnings+1.6%+8.0%
−4%0+4%+8%Aug 3Aug 11earnings+1.6%+8.0%
CRSP +8.0%S&P 500 +1.6%
−4%0+4%+8%Aug 3Aug 11report 4:24pm ETearnings+2.5%+8.0%
−4%0+4%+8%Aug 3Aug 11earnings+2.5%+8.0%
CRSP +8.0%NASDAQ +2.5%
+3.29%
Day of report
+7.06%
Next session
+7.95%
One week

Did CRSP Beat Earnings? Q2 2026 Results

CRISPR Therapeutics delivered a notably stronger-than-expected second quarter, posting an adjusted loss of $0.94 per share against a consensus estimate of $1.18, a beat of 20.59%, while revenue of $10.18 million cleared the $7.43 million estimate by 37.03% and reflected a 1,041.4% increase from the year-ago period. The primary driver was the emergence of $10.00 million in collaboration revenue, tied to accelerating commercial momentum behind CASGEVY, the gene-editing therapy co-developed with Vertex, which generated $76.00 million in partner-reported revenue during the quarter, representing 151% year-over-year growth. The net loss narrowed sharply to $91.15 million from $208.55 million a year prior, aided by a steep reduction in acquired in-process R&D expenses. The company's cash position stood at $2.36 billion as of June 30, 2026, bolstered by a convertible notes offering earlier this year. Morgan Stanley has recently lifted its price target on the stock, citing the CASGEVY label expansion to patients as young as two and upcoming pipeline readouts, including CTX310 durability data and zugo-cel autoimmune updates, as key catalysts heading into the second half of 2026.

Key Takeaways
  • CASGEVY revenue grew 151% year-over-year and 78% quarter-over-quarter to $76 million
  • FDA approval of CASGEVY for children as young as 2 years old expanded eligible patient population by approximately 5,500
  • Net loss narrowed significantly due to lower acquired in-process R&D expenses and growing CASGEVY revenue share
  • German reimbursement secured for CASGEVY for eligible patients 12 years and older

“The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform. CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline.”

CRISPR Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

CRISPR Therapeutics expects multiple milestones in the second half of 2026, including: a CTX310 Phase 1b clinical update and ESC Congress presentation of durability data (August 28, 2026); CTX611 Phase 2 update in total knee arthroplasty; further zugo-cel autoimmune and immuno-oncology clinical updates; an Lp(a) program (CTX321) update; nomination of up to two additional siRNA targets; and continued expansion of CASGEVY commercial access through regulatory submissions and reimbursement efforts globally, including pediatric submissions in Saudi Arabia and the UK.

CRSP YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$-120,000,000$-80,000,000$-40,000,000$0$891,998$10.2MRevenue$-78,778,046$-117,269,000Operating Income$-58,323,629$-91,154,000Net Income
$-120,000,000$-80,000,000$-40,000,000$0RevenueOperating IncomeNet Income

CRSP Revenue by Segment

CASGEVY$76.0M+151.0%

Figures from SEC filings and company reports. Not investment advice.